Breaking News Instant updates and real-time market news.

INSY

Insys Therapeutics

$4.47

0.05 (1.13%)

06:17
01/09/19
01/09
06:17
01/09/19
06:17

Former Insys CEO Babich to plead guilty in kickback case, Reuters reports

Michael Babich, who resigned as the CEO of Insys Therapeutics in 2015, is expected to plead guilty to conspiracy and mail fraud charges in his participation in a scheme to pay doctors bribes in exchange for prescribing an addictive opioid medication, Reuters reports. His plea comes weeks before a five former Insys executives and managers including John Kapoor, the company's founder and former chairman, are scheduled to face trial over what prosecutors claim was their roles in the wide-ranging scheme. Reference Link

  • 09

    Jan

INSY Insys Therapeutics
$4.47

0.05 (1.13%)

03/09/18
PIPR
03/09/18
DOWNGRADE
Target $4
PIPR
Underweight
Insys Therapeutics downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray analyst David Amsellem downgraded Insys Therapeutics to Underweight and cut his price target for the shares to $4 from $5. The analyst sees "no basis in reality" for the company's guidance of relatively stable total sales in 2018 versus 2017 given the nature of the opioid crisis. Further, the weak rollout of Syndros "also does not inspire confidence" in the 2018 guidance, Amsellem tells investors in a research note.
08/10/18
PIPR
08/10/18
NO CHANGE
Target $4
PIPR
Underweight
Insys DOJ settlement does not remove downside risk, says Piper Jaffray
Piper Jaffray analyst David Amsellem says the settlement with the Department of Justice does not mean there isn't downside risk in shares of Insys Therapeutics. For a $600M market capitalization, investors are getting a sublingual form of buprenorphine that was "roundly rejected" by an FDA panel in May, a cannabidiol product that has yet to demonstrate proof-of-concept in a well-controlled trial, a product in Syndros that has minimal sales after approximately one year of active promotion, and a declining asset in Subsys that has limited profitability, Amsellem tells investors in a research note following Insys' Q2 results. The analyst does not believe the shares are "adequately risk-adjusted." He reiterates an Underweight rating on Insys with a $4 price target.
12/19/18
JANY
12/19/18
INITIATION
Target $11
JANY
Buy
Insys Therapeutics assumed with a Buy at Janney Montgomery Scott
Janney Montgomery Scott analyst Yun Zhong assumed coverage of Insys Therapeutics with a Buy rating and fair value estimate of $11, down from the firm's prior $16 estimate. Zhong said Insys is shifting focus from commercializing opioid products to developing cannabinoids and proprietary spray technology, adding that he views the heated discussion during a two-day FDA AdCom on naloxone earlier this week as a "clear sign" for an increased commercial opportunity for Insys. Zhong also believes the data from the cannabidiol programs, if positive, could unlock significant upside potential.

TODAY'S FREE FLY STORIES

STMP

Stamps.com

$198.08

-4.03 (-1.99%)

08:11
02/22/19
02/22
08:11
02/22/19
08:11
Downgrade
Stamps.com rating change  »

Stamps.com downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KL

Kirkland Lake Gold

$36.03

2.6 (7.78%)

08:11
02/22/19
02/22
08:11
02/22/19
08:11
Downgrade
Kirkland Lake Gold rating change  »

Kirkland Lake Gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

CMRX

Chimerix

$1.92

-0.04 (-2.04%)

08:10
02/22/19
02/22
08:10
02/22/19
08:10
Hot Stocks
Chimerix presents results from Phase 3 SUPPRESS trial »

Chimerix announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDOC

Teladoc

$68.25

-1.25 (-1.80%)

08:09
02/22/19
02/22
08:09
02/22/19
08:09
Recommendations
Teladoc analyst commentary  »

Teladoc view remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

CLSH

CLS Holdings

08:08
02/22/19
02/22
08:08
02/22/19
08:08
Initiation
CLS Holdings initiated  »

CLS Holdings initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATNI

ATN International

$59.50

-15.62 (-20.79%)

08:08
02/22/19
02/22
08:08
02/22/19
08:08
Upgrade
ATN International rating change  »

ATN International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 22

    Mar

  • 28

    Mar

MDRX

Allscripts

$11.93

-0.21 (-1.73%)

08:07
02/22/19
02/22
08:07
02/22/19
08:07
Downgrade
Allscripts rating change  »

Allscripts downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTV

Veritiv

$35.55

-0.26 (-0.73%)

08:07
02/22/19
02/22
08:07
02/22/19
08:07
Hot Stocks
Veritiv to optimize wide format products business »

Veritiv announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 28

    Mar

APPN

Appian

$38.73

0.41 (1.07%)

08:06
02/22/19
02/22
08:06
02/22/19
08:06
Recommendations
Appian analyst commentary  »

Appian getting closer to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 07

    Mar

K

Kellogg

$58.33

-0.13 (-0.22%)

08:06
02/22/19
02/22
08:06
02/22/19
08:06
Hot Stocks
Kellogg elects Erica Mann, Roderick Gillum to board »

Kellogg announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 03

    Mar

SYNL

Synalloy

$12.94

0.11 (0.86%)

08:05
02/22/19
02/22
08:05
02/22/19
08:05
Hot Stocks
Synalloy announces stock repurchase program for up to 850,000 shares »

Synalloy announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIDU

Baidu

$171.72

0.64 (0.37%)

08:05
02/22/19
02/22
08:05
02/22/19
08:05
Recommendations
Baidu analyst commentary  »

Baidu price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

MYL

Mylan

$31.06

-0.54 (-1.71%)

08:04
02/22/19
02/22
08:04
02/22/19
08:04
Hot Stocks
Mylan announces U.S. launch of generic Suboxone Sublingual Film »

Mylan announced the U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

OBLN

Obalon Therapeutics

$2.17

0.07 (3.33%)

08:03
02/22/19
02/22
08:03
02/22/19
08:03
Earnings
Obalon Therapeutics reports Q4 EPS (39c), consensus (36c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 18

    May

TTD

Trade Desk

$150.18

0.07 (0.05%)

08:03
02/22/19
02/22
08:03
02/22/19
08:03
Recommendations
Trade Desk analyst commentary  »

Trade Desk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 06

    Mar

HTH

Hilltop Holdings

$19.63

0.06 (0.31%)

08:03
02/22/19
02/22
08:03
02/22/19
08:03
Hot Stocks
Hilltop Holdings announces retirement of co-CEO Alan White »

Hilltop Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$78.76

-1.26 (-1.57%)

, VYGR

Voyager Therapeutics

$10.70

-0.19 (-1.74%)

08:02
02/22/19
02/22
08:02
02/22/19
08:02
Hot Stocks
AbbVie, Voyager Therapeutics partner to develop vectorized antibodies »

AbbVie (ABBV) and Voyager…

ABBV

AbbVie

$78.76

-1.26 (-1.57%)

VYGR

Voyager Therapeutics

$10.70

-0.19 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 11

    Mar

  • 18

    May

VNTR

Venator Materials

$6.40

0.115 (1.83%)

08:01
02/22/19
02/22
08:01
02/22/19
08:01
Initiation
Venator Materials initiated  »

Venator Materials resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

08:01
02/22/19
02/22
08:01
02/22/19
08:01
Recommendations
Kraft Heinz analyst commentary  »

Kraft Heinz price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCS

Marcus

08:01
02/22/19
02/22
08:01
02/22/19
08:01
Recommendations
Marcus analyst commentary  »

Marcus price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Apr

  • 02

    Apr

  • 06

    Jun

NE

Noble Corp.

$3.12

-0.2 (-6.02%)

08:00
02/22/19
02/22
08:00
02/22/19
08:00
Downgrade
Noble Corp. rating change  »

Noble Corp. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

SO

Southern Company

$50.22

0.48 (0.97%)

07:59
02/22/19
02/22
07:59
02/22/19
07:59
Upgrade
Southern Company rating change  »

Southern Company upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDRX

Allscripts

$11.93

-0.21 (-1.73%)

07:59
02/22/19
02/22
07:59
02/22/19
07:59
Downgrade
Allscripts rating change  »

Allscripts downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ES

Eversource

$70.50

0.23 (0.33%)

07:58
02/22/19
02/22
07:58
02/22/19
07:58
Downgrade
Eversource rating change  »

Eversource downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

KEYS

Keysight Technologies

$81.74

0.67 (0.83%)

07:56
02/22/19
02/22
07:56
02/22/19
07:56
Recommendations
Keysight Technologies analyst commentary  »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.